MiMedx Group, Inc

MDXG Healthcare Biotechnology

MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024. In the quarter to June 2026, revenue fell 34.7%, EPS fell 242.9%, free cash flow fell 174.8% and total debt fell 6.80%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

4.43 0.25 −5.34%
Market cap
$682.2M
P/E
111×
Fwd P/E
−31.2×
Dividend yield
—
F-score
5/9
Altman Z
9.38
Beneish M
−2.68
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

24.93 20.52 18.81 96.25
P/S ratio
2.63 2.39 1.51 1.60
P/FCF ratio
15.47 13.71 8.46 12.81
P/Operating CF
35.23 40.09 312.06 (56.82)
P/B ratio
4.32 3.90 2.41 2.63
EV/Sales
2.31 2.04 1.14 1.27
EV/EBITDA
13.27 10.82 8.40 22.07
EV/FCF
13.61 11.68 6.41 10.14
Current Ratio
4.41 4.32 5.39 5.33
Net Debt/EBITDA
(4.51) (6.10) 9.85 7.01
Debt/Equity
0.08 0.07 0.07 0.08
Earnings Yield
4.01% 4.87% 5.32% 1.04%
Free Cash Flow Yield
6.47% 7.29% 11.82% 7.81%
Free Cash Flow per Share
0.20 0.17 0.01 (0.07)
Book value per Share
1.61 1.74 1.64 1.46
Free Cash Flow
29.14 24.71 1.24 (10.65)
EV/EBIT
16.88 13.34 11.22 51.47
Other line items

Show all line items

Columns are period end dates